Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Change in Account Payables (2022 - 2025)

Praxis Precision Medicines has reported Change in Account Payables over the past 4 years, most recently at -$6.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$6.2 million for Q4 2025, down 149.56% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (up 80.2% YoY), and the annual figure for FY2025 was $12.1 million, up 80.2%.
  • Change in Account Payables for Q4 2025 was -$6.2 million at Praxis Precision Medicines, down from $2.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for PRAX hit a ceiling of $10.4 million in Q1 2025 and a floor of -$9.0 million in Q2 2023.
  • Median Change in Account Payables over the past 4 years was $546500.0 (2023), compared with a mean of $865437.5.
  • Biggest five-year swings in Change in Account Payables: tumbled 519.89% in 2023 and later surged 883.67% in 2024.
  • Praxis Precision Medicines' Change in Account Payables stood at $4.6 million in 2022, then tumbled by 128.55% to -$1.3 million in 2023, then plummeted by 91.07% to -$2.5 million in 2024, then plummeted by 149.56% to -$6.2 million in 2025.
  • The last three reported values for Change in Account Payables were -$6.2 million (Q4 2025), $2.0 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.